Apellis PharmaceuticalsAPLS
APLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 702
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
209% more call options, than puts
Call options by funds: $128M | Put options by funds: $41.5M
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
8% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 40
2% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 92
0.36% less ownership
Funds ownership: 99.78% [Q2] → 99.42% (-0.36%) [Q3]
0% less funds holding
Funds holding: 261 [Q2] → 260 (-1) [Q3]
25% less capital invested
Capital invested by funds: $4.64B [Q2] → $3.49B (-$1.15B) [Q3]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
14%
downside
Avg. target
$41
36%
upside
High target
$60
99%
upside
13 analyst ratings
6 positive
46%
7 neutral
54%
0 negative
0%
RBC Capital Luca Issi 17% 1-year accuracy 10 / 60 met price target | 14%downside $26 | Sector Perform Reiterated | 21 Jan 2025 |
HC Wainwright & Co. Douglas Tsao 31% 1-year accuracy 54 / 173 met price target | 89%upside $57 | Buy Reiterated | 14 Jan 2025 |
Goldman Sachs Salveen Richter 19% 1-year accuracy 3 / 16 met price target | 19%upside $36 | Neutral Downgraded | 17 Dec 2024 |
Morgan Stanley Judah Frommer 33% 1-year accuracy 3 / 9 met price target | 3%upside $31 | Equal-Weight Initiated | 21 Nov 2024 |
Baird Colleen Kusy 25% 1-year accuracy 5 / 20 met price target | 83%upside $55 | Outperform Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 18 articles about APLS published over the past 30 days
Neutral
Accesswire
13 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Apellis Pharmaceuticals, Inc. (APLS) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
4 days ago
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Apellis Pharmaceuticals, Inc. (APLS) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
6 days ago
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Apellis Pharmaceuticals, Inc. (APLS) And Encourages Investors to Connect
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Apellis Pharmaceuticals, Inc. (APLS) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Neutral
GlobeNewsWire
1 week ago
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues for the fourth quarter and the full year 2024 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH) as well as its strategic priorities for continued growth.
Neutral
Accesswire
1 week ago
APLS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS). Investors who purchased Apellis securities prior to January 28, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLS.
Charts implemented using Lightweight Charts™